FDA Accepts Biodel’s New Drug Application for Review
FDA Accepts Biodel’s New Drug Application for Review
Shares
Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel’s proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs. The new drug has been tested in more than 875 patients who participated in Phase 1, 2 and 3 clinical trials of the drug in the United States, Germany and India.
Gary Taubes' Case for the Keto Diet: A Book Review “We believe than an injustice is being perpetrated that has to be righted.” Gary Taubes doesn’t mince words in his new book, The Case for Keto. The text is his…
FDA approves Lyumjev, Lilly’s New Rapid-Acting Insulin The U.S. FDA has approved Lyumjev, Lilly’s new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Lyumjev (insulin lispro-aabc injection, 100 units/mL…
FDA: New Medtronic 770G Insulin Pump Approved for Ages 2+ The FDA has approved Medtronic's 770G insulin pump, the newest hybrid closed loop system, for use in patients as young as 2 years old. Parents of young children with Type…
FDA Green Lights Trials of New Type 1 Diabetes Stem Cell… The United States Food and Drug Administration (FDA) has given the green light for experimental trials of a truly new therapy for Type 1 diabetes. The new therapy, named VX-880,…
Did a Common Cholesterol Drug Reverse One Teen’s Type 1… Did fenofibrate – a common cholesterol drug – reverse one 19-year old woman’s newly diagnosed Type 1 diabetes? This is the question at the heart of a tantalizing medical mystery…
We use cookies to optimize our website and our service.
Functional cookies Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.